Jubilant Life Sciences, an integrated global Pharmaceutical and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval for Itraconazole Capsules, 100 mg, the generic version of Sporanox of Janssen Pharmaceuticals, which is used for the treatment of fungal infections.
The company has received 8 approvals from the USFDA during the year. As on December 31, 2016, the pharma major had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved.
Jubilant Life Sciences is engaged in manufacturing and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.